Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 28, 2011 Filed Mar 2, 2011 00:41 UTC |
HILL CHARLES HExecutive Vice President
|
Tax withholdingCommon Stock | 4,795 | $19.24 | $92,255.80 |
DisclosureSEC source: 0001225208-11-007973 · doc4.xml · nonDerivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,603 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 00:44 UTC |
SUSMAN SALLYExecutive Vice President
|
Tax withholdingCommon Stock | 20,976 | $19.24 | $403,578.24 |
DisclosureSEC source: 0001225208-11-007974 · doc4.xml · nonDerivative · entry 1 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202,365 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 00:44 UTC |
PECK KRISTIN CExecutive Vice President
|
Tax withholdingCommon Stock | 1,705 | $19.24 | $32,804.20 |
DisclosureSEC source: 0001225208-11-007975 · doc4.xml · nonDerivative · entry 1 PECK KRISTIN C · CIK 0001488267 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,090 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 00:45 UTC |
RICCIARDI NATALE SSenior Vice President
|
Tax withholdingCommon Stock | 7,724 | $19.24 | $148,609.76 |
DisclosureSEC source: 0001225208-11-007976 · doc4.xml · nonDerivative · entry 1 RICCIARDI NATALE S · CIK 0001107158 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,778 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 00:45 UTC |
SIMMONS DAVID SBusiness Unit President
|
Tax withholdingCommon Stock | 2,552 | $19.24 | $49,100.48 |
DisclosureSEC source: 0001225208-11-007977 · doc4.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,382 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 00:49 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 1,276 | $19.24 | $24,550.24 |
DisclosureSEC source: 0001225208-11-007978 · doc4.xml · nonDerivative · entry 1 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,263 F1 · kind: Represents withholding of shares to satisfy tax obligations upon vesting of restricted stock units. Read SEC document |
| February 28, 2011 Filed Mar 2, 2011 00:50 UTC |
READ IAN CDirector · President & CEO
|
GrantPhantom Stock Units SSP · Derivative | 189 | $19.24 | $3,636.36 |
DisclosureSEC source: 0001225208-11-007979 · doc4.xml · derivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,212 Underlying: Common Stock · 189 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Inc. Nonfunded Deferred Compensation and Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:39 UTC |
SIMMONS DAVID SBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 135,397 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000078003-11-000001 · primary_doc.xml · derivative · entry 6 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,397 Underlying: Common Stock · 135,397 shares Expires 2018-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:39 UTC |
SIMMONS DAVID SBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 163,551 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0000078003-11-000001 · primary_doc.xml · derivative · entry 5 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,551 Underlying: Common Stock · 163,551 shares Expires 2016-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:39 UTC |
SIMMONS DAVID SBusiness Unit President
|
Tax withholdingCommon Stock | 628 | $18.90 | $11,869.20 |
DisclosureSEC source: 0000078003-11-000001 · primary_doc.xml · nonDerivative · entry 3 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,934 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:39 UTC |
SIMMONS DAVID SBusiness Unit President
|
GrantCommon Stock | 1,731 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-11-000001 · primary_doc.xml · nonDerivative · entry 2 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,562 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:39 UTC |
SIMMONS DAVID SBusiness Unit President
|
GrantCommon Stock | 37,057 | $0.00 | $0.00 |
DisclosureSEC source: 0000078003-11-000001 · primary_doc.xml · nonDerivative · entry 1 SIMMONS DAVID S · CIK 0001508519 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 132,831 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:24 UTC |
SCHULMAN AMY WExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 145,068 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001223203-11-000005 · primary_doc.xml · derivative · entry 5 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,068 Underlying: Common Stock · 145,068 shares Expires 2018-02-24 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:24 UTC |
SCHULMAN AMY WExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 175,234 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001223203-11-000005 · primary_doc.xml · derivative · entry 4 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,234 Underlying: Common Stock · 175,234 shares Expires 2016-02-24 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Mar 1, 2011 02:24 UTC |
SCHULMAN AMY WExecutive Vice President
|
GrantCommon Stock | 51,615 | $0.00 | $0.00 |
DisclosureSEC source: 0001223203-11-000005 · primary_doc.xml · nonDerivative · entry 1 SCHULMAN AMY W · CIK 0001438226 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 242,194 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:09 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 135,397 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007651 · doc4.xml · derivative · entry 6 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,397 Underlying: Common Stock · 135,397 shares Expires 2018-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:09 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 163,551 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007651 · doc4.xml · derivative · entry 5 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,551 Underlying: Common Stock · 163,551 shares Expires 2016-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:09 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
Tax withholdingCommon Stock | 1,182 | $18.90 | $22,339.80 |
DisclosureSEC source: 0001225208-11-007651 · doc4.xml · nonDerivative · entry 3 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 217,035 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:09 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantCommon Stock | 2,882 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007651 · doc4.xml · nonDerivative · entry 2 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,217 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:09 UTC |
BRANDICOURT OLIVIERBusiness Unit President
|
GrantCommon Stock | 37,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007651 · doc4.xml · nonDerivative · entry 1 BRANDICOURT OLIVIER · CIK 0001508518 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 215,335 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC |
READ IAN CDirector · President & CEO
|
GrantStock Appreciation Rights · Derivative | 420,000 | $0.00 Strike: $20.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · derivative · entry 7 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 420,000 Underlying: Common Stock · 420,000 shares Expires 2018-02-24 F6 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. The grant price is equal to 125% of the closing price of Pfizer common stock on December 3, 2010, which was the last business day before Mr. Read was elected President and Chief Executive Officer of the Company. F6 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. The grant price is equal to 125% of the closing price of Pfizer common stock on December 3, 2010, which was the last business day before Mr. Read was elected President and Chief Executive Officer of the Company. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC |
READ IAN CDirector · President & CEO
|
GrantStock Appreciation Rights · Derivative | 483,559 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · derivative · entry 6 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 483,559 Underlying: Common Stock · 483,559 shares Expires 2018-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. The grant price is equal to the closing price of Pfizer common stock on the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. The grant price is equal to the closing price of Pfizer common stock on the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC |
READ IAN CDirector · President & CEO
|
GrantStock Appreciation Rights · Derivative | 584,112 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · derivative · entry 5 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584,112 Underlying: Common Stock · 584,112 shares Expires 2016-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. The grant price is equal to the closing price of Pfizer common stock on the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. The grant price is equal to the closing price of Pfizer common stock on the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC |
READ IAN CDirector · President & CEO
|
Tax withholdingCommon Stock | 4,239 | $18.90 | $80,117.10 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · nonDerivative · entry 3 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 753,837 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC |
READ IAN CDirector · President & CEO
|
GrantCommon Stock | 11,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · nonDerivative · entry 2 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 758,076 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:10 UTC |
READ IAN CDirector · President & CEO
|
GrantCommon Stock | 160,137 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007653 · doc4.xml · nonDerivative · entry 1 READ IAN C · CIK 0001372915 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 746,105 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:17 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 28,288 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007657 · doc4.xml · derivative · entry 6 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,288 Underlying: Common Stock · 28,288 shares Expires 2018-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:17 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantStock Appreciation Rights · Derivative | 34,171 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007657 · doc4.xml · derivative · entry 5 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,171 Underlying: Common Stock · 34,171 shares Expires 2016-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:17 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
Tax withholdingCommon Stock | 1,005 | $18.90 | $18,994.50 |
DisclosureSEC source: 0001225208-11-007657 · doc4.xml · nonDerivative · entry 3 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,264 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:17 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 2,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007657 · doc4.xml · nonDerivative · entry 2 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,269 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:17 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
GrantCommon Stock | 7,742 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007657 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,542 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:23 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 174,081 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007662 · doc4.xml · derivative · entry 6 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,081 Underlying: Common Stock · 174,081 shares Expires 2018-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:23 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 210,280 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007662 · doc4.xml · derivative · entry 5 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,280 Underlying: Common Stock · 210,280 shares Expires 2016-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:23 UTC |
DAMELIO FRANK AExecutive Vice President
|
Tax withholdingCommon Stock | 4,352 | $18.90 | $82,252.80 |
DisclosureSEC source: 0001225208-11-007662 · doc4.xml · nonDerivative · entry 3 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 509,484 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:23 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantCommon Stock | 11,971 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007662 · doc4.xml · nonDerivative · entry 2 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 513,836 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:23 UTC |
DAMELIO FRANK AExecutive Vice President
|
GrantCommon Stock | 75,436 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007662 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 501,865 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:30 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 174,081 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007669 · doc4.xml · derivative · entry 3 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,081 Underlying: Common Stock · 174,081 shares Expires 2018-02-24 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:30 UTC |
Dolsten MikaelPresident R&D
|
GrantStock Appreciation Rights · Derivative | 210,280 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007669 · doc4.xml · derivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,280 Underlying: Common Stock · 210,280 shares Expires 2016-02-24 F2 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F2 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:30 UTC |
Dolsten MikaelPresident R&D
|
GrantCommon Stock | 68,290 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007669 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 212,298 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:36 UTC |
Germano Geno JBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 135,397 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007681 · doc4.xml · derivative · entry 4 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,397 Underlying: Common Stock · 135,397 shares Expires 2018-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:36 UTC |
Germano Geno JBusiness Unit President
|
GrantStock Appreciation Rights · Derivative | 163,551 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007681 · doc4.xml · derivative · entry 3 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,551 Underlying: Common Stock · 163,551 shares Expires 2016-02-24 F3 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F3 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:36 UTC |
Germano Geno JBusiness Unit President
|
GrantCommon Stock | 37,057 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007681 · doc4.xml · nonDerivative · entry 1 Germano Geno J · CIK 0001424383 · Business Unit President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,130 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:44 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 65,280 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007683 · doc4.xml · derivative · entry 6 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,280 Underlying: Common Stock · 65,280 shares Expires 2018-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:44 UTC |
HILL CHARLES HExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 78,855 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007683 · doc4.xml · derivative · entry 5 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,855 Underlying: Common Stock · 78,855 shares Expires 2016-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:44 UTC |
HILL CHARLES HExecutive Vice President
|
Tax withholdingCommon Stock | 486 | $18.90 | $9,185.40 |
DisclosureSEC source: 0001225208-11-007683 · doc4.xml · nonDerivative · entry 3 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,398 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:44 UTC |
HILL CHARLES HExecutive Vice President
|
GrantCommon Stock | 1,339 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007683 · doc4.xml · nonDerivative · entry 2 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,884 F2 · shares: The reported transaction constitutes the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:44 UTC |
HILL CHARLES HExecutive Vice President
|
GrantCommon Stock | 17,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-11-007683 · doc4.xml · nonDerivative · entry 1 HILL CHARLES H · CIK 0001508517 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,545 F1 · shares: The reported transaction constitutes the grant of restricted stock units, which are subject to certain vesting requirements. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:51 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 28,288 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007686 · doc4.xml · derivative · entry 6 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,288 Underlying: Common Stock · 28,288 shares Expires 2018-02-24 F5 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. F5 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the seventh anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:51 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
GrantStock Appreciation Rights · Derivative | 34,171 | $0.00 Strike: $18.90 | $0.00 |
DisclosureSEC source: 0001225208-11-007686 · doc4.xml · derivative · entry 5 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,171 Underlying: Common Stock · 34,171 shares Expires 2016-02-24 F4 · derivative.exercise_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. F4 · derivative.expiration_date: The stock appreciation rights, which are subject to certain vesting requirements, will be settled in shares of Pfizer common stock on the fifth anniversary of the date of grant. Read SEC document |
| February 24, 2011 Filed Feb 28, 2011 23:51 UTC |
LANKLER DOUGLAS MExecutive Vice President
|
Tax withholdingCommon Stock | 315 | $18.90 | $5,953.50 |
DisclosureSEC source: 0001225208-11-007686 · doc4.xml · nonDerivative · entry 3 LANKLER DOUGLAS M · CIK 0001488270 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,539 F3 · shares: The reported transaction constitutes the withholding of shares to satisfy tax obligations upon the earn-out of Performance Share Awards (including dividend equivalents thereon). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.